Nobori® Stent

**Nobori® - Drug Eluting Stent - Product Information**

Nobori® Drug Eluting Stent is indicated for improving luminal diameter and reducing in-stent restenosis for the treatment of coronary artery lesions.

Nobori® stent has an innovative design, with biolimus A9 drug and biodegradable polymer, coated only on the abluminal side of the stent. This technology provides efficacy and preserves safety over time.

**Technical Specifications**

- Low entry profile 0.43 mm enhances crossability
- Low compliant balloon provides an optimal stent expansion

Open cell area provides wide side-branch access to treat bifurcation lesions:

M-Coating provides excellent trackability:

**General Specifications**

<table>
<thead>
<tr>
<th>Specification</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stent material</td>
<td>316 L stainless steel</td>
</tr>
<tr>
<td>Guide wire diameter</td>
<td>0.014” (0.36 mm)</td>
</tr>
<tr>
<td>Balloon material</td>
<td>Nylon</td>
</tr>
<tr>
<td>Nominal pressure</td>
<td>8 atm (810 kPa)</td>
</tr>
<tr>
<td>Rated burst pressure</td>
<td>16 atm (1621 kPa) - 2.5 to 3.0 mm</td>
</tr>
<tr>
<td></td>
<td>14 atm (1418 kPa) - 3.5 mm</td>
</tr>
<tr>
<td>Stent crossing profile</td>
<td>0.044” (1.11 mm) - 3.0 mm</td>
</tr>
<tr>
<td>Usable length of catheter</td>
<td>145 cm</td>
</tr>
</tbody>
</table>

**Biodegradable Polymer**

**Drug - Biolimus A9™**

**Reference Codes**

**Related Content**

- Nobori® brochure [pdf - 1.3 Mb]

Pictures taken by Terumo - Data on file at Terumo
Nobori® Drug Eluting Stent has a unique design with an asymmetric coating and biodegradable polymer. The biodegradable PLA (Polyactid Acid) is a naturally occurring polymer with a long history of medical applications. This innovative concept allows for simultaneous polymer degradation and drug release.

**Key Characteristics**

**Abluminal Coating**
Abluminal coating maximizes drug release into the vessel wall and minimizes systemic effect.
- Targeted drug release into the vessel wall
- Minimal systemic effect
- Better stent endothelialization with possible positive impact on safety

**Fully Biodegradable Polymer**
PLA completely degrades by hydrolysis to carbon dioxide and water. Degradation of the polymer may improve long term safety by:
- Reducing chronic sensitivity
- Eliminating the potential problem of remnant drug inside the coating
- Abolishing chances of delamination or late failure of coating
- Simultaneous polymer degradation and release of drug into tissue

---


---

**Related Content**

**Nobori® Stent**

**Product Information**

**Technical Specifications**

**Biodegradable Polymer**

---

**Related Content**

**Highlights**

**NOBORI 2**
Largest real-life registry of Nobori® stent. Enrolled 3068 consecutive patients with coronary artery disease eligible for treatment with Drug-Eluting Stent.
The 3 year clinical results of NOBORI 2 study show consistently low occurrence of clinical events throughout the trial.

Find out more about the NOBORI 2 three year results
Biolimus A9™, a new limus drug designed for stent application, provides efficacy. This anti-proliferative and anti-inflammatory drug reduces neo-intimal proliferation.

Nobori® Drug Eluting Stent is indicated for improving luminal diameter and reducing in-stent restenosis for the treatment of coronary artery lesions. Nobori® stent has an innovative design, with biolimus A9™ drug and biodegradable polymer, coated only on the abluminal side of the stent. This technology provides efficacy and preserves safety over time.

Biolimus A9™, a new limus-drug designed for stent application, provides efficacy. This anti-proliferative and anti-inflammatory drug reduces neo-intimal proliferation.

Precise release kinetics with an initial burst and sustained elution through polymer degradation assure long term efficacy.

Quantity on stent: + 15.6 µg/mm

Lipophilicity comparison

Test Method:

3 Chevalier B et al.: Randomized comparison of Nobori®, biolimus A9™-eluting coronary stent with a Taxus®, paclitaxel eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial. EuroInterv 2007; 2,426-34

Reference Codes
Related Content
Nobori® Drug Eluting Stent is indicated for improving luminal diameter and reducing in-stent restenosis for the treatment of coronary artery lesions.

Nobori® stent has an innovative design, with biolimus A9 drug and biodegradable polymer, coated only on the abluminal side of the stent. This technology provides efficacy and preserves safety over time.

Please quote above item reference codes when placing an order.

---

**Related Content**

- [Nobori® brochure](#) [pdf - 1.3 Mb]

---

Pictures taken by Terumo - Data on file at Terumo

Biolimus A9™ is a registered trade mark of Biosensors